{name}
{subtitle}
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~70 mi. (Mérida, Mexico, +247 more cities)
facility
Local Institution
biomarker
ER Positive, +1 more biomarker
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~70 mi. (Mérida, Mexico, +383 more cities)
facility
Merida | Investigacion Clinica
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type